---
title: "Xinxiang Chem released its 2024 annual performance, turning a loss into a profit of 246 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233434264.md"
description: "According to the Zhitong Finance APP, Xinxiang Chem released its 2024 annual report. During the reporting period, the company achieved operating revenue of 7.366 billion yuan, a year-on-year decrease of 0.18%. The net profit attributable to shareholders of the listed company was 246 million yuan. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 232 million yuan. The basic earnings per share were 0.1574 yuan"
datetime: "2025-03-27T10:10:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233434264.md)
  - [en](https://longbridge.com/en/news/233434264.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233434264.md)
generator: "portal-rs"
---

# Xinxiang Chem released its 2024 annual performance, turning a loss into a profit of 246 million yuan

According to the Zhitong Finance APP, Xinxiang Chem (000949.SZ) released its annual report for 2024. During the reporting period, the company achieved operating revenue of 7.366 billion yuan, a year-on-year decrease of 0.18%. The net profit attributable to shareholders of the listed company was 246 million yuan. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 232 million yuan. The basic earnings per share were 0.1574 yuan

### Related Stocks

- [000949.CN](https://longbridge.com/en/quote/000949.CN.md)

## Related News & Research

- [Aciselsan Cancels Dividend Proposal After 2024 General Assembly Is Not Held](https://longbridge.com/en/news/297937908.md)
- [Veteran Capital shares set to resume trading on TSX Venture Exchange after halt since June 2024](https://longbridge.com/en/news/297955724.md)
- [Epinephrine injection recalled over potentially fatal health risks](https://longbridge.com/en/news/298065018.md)
- [Spiber says me ISSEY MIYAKE launches bag using Brewed Protein fiber](https://longbridge.com/en/news/297969190.md)
- [Biohit says scientific review backs serum biomarker triage to target endoscopy for gastric cancer risk](https://longbridge.com/en/news/297887371.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**